From Interferon to Checkpoint Inhibition Therapy-A Systematic Review of New Immune-Modulating Agents in Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC).
Susanne DeiningerPeter TörzsökMichael MitterbergerMaximilian PallaufDavid OswaldChristian DeiningerLukas LusuardiPublished in: Cancers (2022)
CPIs and other IM agents now offer an increasing opportunity for bladder-preserving strategies. Studies on different substances are ongoing and will yield new findings.